JP Morgan Chase
GMAB icon

JP Morgan Chase’s Genmab GMAB Stock Holding History

JP Morgan Chase’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.4M Buy
744,815
+522,208
+235% +$13.9M ﹤0.01% 2248
2026
Q1 		$5.75M Sell
222,607
-5,881
-3% -$176K ﹤0.01% 3197
2025
Q4 		$7.04M Buy
228,488
+110,307
+93% +$3.44M ﹤0.01% 3012
2025
Q3 		$3.62M Sell
118,181
-815,128
-87% -$19.9M ﹤0.01% 3632
2025
Q2 		$19.3M Buy
933,309
+135,814
+17% +$2.79M ﹤0.01% 1979
2025
Q1 		$15.6M Buy
797,495
+389,882
+96% +$8.18M ﹤0.01% 2129
2024
Q4 		$8.51M Buy
407,613
+394,670
+3,049% +$8.67M ﹤0.01% 2847
2024
Q3 		$316K Sell
12,943
-14,567
-53% -$389K ﹤0.01% 5175
2024
Q2 		$691K Sell
27,510
-4,374
-14% -$124K ﹤0.01% 4502
2024
Q1 		$954K Sell
31,884
-104,019
-77% -$3.06M ﹤0.01% 4380
2023
Q4 		$4.33M Sell
135,903
-40,091
-23% -$1.26M ﹤0.01% 3219
2023
Q3 		$6.21M Buy
175,994
+52,528
+43% +$2M ﹤0.01% 2669
2023
Q2 		$4.69M Sell
123,466
-43,281
-26% -$1.73M ﹤0.01% 2919
2023
Q1 		$6.3M Sell
166,747
-32,546
-16% -$1.25M ﹤0.01% 2638
2022
Q4 		$8.45M Buy
199,293
+19,548
+11% +$805K ﹤0.01% 2402
2022
Q3 		$5.78M Buy
179,745
+6,357
+4% +$223K ﹤0.01% 2620
2022
Q2 		$5.63M Buy
173,388
+38,272
+28% +$1.24M ﹤0.01% 2686
2022
Q1 		$4.89M Buy
135,116
+40,444
+43% +$1.39M ﹤0.01% 3023
2021
Q4 		$3.74M Sell
94,672
-23,403
-20% -$976K ﹤0.01% 3300
2021
Q3 		$5.16M Buy
118,075
+34,618
+41% +$1.55M ﹤0.01% 3000
2021
Q2 		$3.41M Buy
83,457
+82,779
+12,209% +$3.19M ﹤0.01% 3371
2021
Q1 		$22K Sell
678
-149
-18% -$5.6K ﹤0.01% 5689
2020
Q4 		$33K Buy
827
+272
+49% +$10.2K ﹤0.01% 5233
2020
Q3 		$21K Sell
555
-17
-3% -$615 ﹤0.01% 5135
2020
Q2 		$20K Buy
572
+422
+281% +$11.5K ﹤0.01% 5039
2020
Q1 		$4K Sell
150
-2,269
-94% -$50.6K ﹤0.01% 5144
2019
Q4 		$54K Buy
2,419
+1,813
+299% +$39.6K ﹤0.01% 5103
2019
Q3 		$12K Buy
+606
New +$11.9K ﹤0.01% 5483

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

JP Morgan Chase's GMAB Position: Q2 2026 in Review

JP Morgan Chase increased its Genmab (GMAB) stake by 235% in Q2 2026, buying an estimated $13.9M and bringing the position to 744,815 shares worth $19.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2248.

JP Morgan Chase first reported a position in GMAB in Q3 2019 and has held it in 28 quarters since. 289 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • JP Morgan Chase held 744,815 shares of Genmab worth $19.4M as of Q2 2026.
  • JP Morgan Chase bought 522,208 Genmab shares in Q2 2026, an estimated $13.9M.
  • Genmab made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #2248 holding.
  • JP Morgan Chase first reported a position in Genmab in Q3 2019 and has held it in 28 quarters since.
  • 289 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.